| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID474076 | Volume of distribution in dog at 2.5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474074 | Bioavailability in rat at 5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474075 | Clearance in dog at 2.5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474064 | Antiinflammatory activity in Lewis rat assessed as reduction in LPS-stimulated TNFalpha accumulation at 1 mg/kg, ig administered 4 hrs before LPS challenge measured after 1.5 hrs by ELISA | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474062 | Antiinflammatory activity in Lewis rat plasma assessed as reduction in LPS-stimulated TNFalpha accumulation at 5 mg/kg, ig administered 4 hrs before LPS challenge measured after 1.5 hrs by ELISA | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474077 | Half life in dog at 2.5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474072 | Volume of distribution in rat at 5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474066 | Intrinsic clearance in human liver microsomes | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474065 | Antiinflammatory activity against LPS-induced TNFalpha production in human whole blood treated 1 hr before LPS challenge measured after 4 hrs by ELISA | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474071 | Clearance in rat at 5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474068 | Displacement of dofetilide from human ERG at 10 uM | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474070 | Antiarthritic activity against collagen-induced arthritis in DBA/1 mouse chronic CIA model assessed as incidence of arthritis at 30 mg/kg, po after 21 days | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474061 | Inhibition of p38beta assessed as gamma-[33P]ATP incorporation by scintillation counting | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474067 | Half life in human liver microsomes | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474060 | Inhibition of p38alpha assessed as gamma-[33P]ATP incorporation by scintillation counting | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474073 | Half life in rat at 5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID474078 | Bioavailability in dog at 2.5 mg/kg, iv | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2009 | Biochemistry, Jul-14, Volume: 48, Issue:27
| Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |